Jefferies Global Healthcare Conference
Logotype for Denali Therapeutics Inc

Denali Therapeutics (DNLI) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Denali Therapeutics Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

AVLAYAH launch and commercial outlook

  • AVLAYAH launched for Hunter syndrome; the U.S. population is ~500, with 375 eligible under the current pediatric label, and ~1,500 additional patients worldwide.

  • The launch has completed two successful quarters; the commercial goal is to become the market leader by treating new patients and capturing prevalent patients switching from current ERT.

  • U.S. annual cost for a 30-kg patient is ~$800,000, versus $500,000 for current ERT; adult label expansion and international access are important growth drivers.

  • The 2026 Q4 revenue guidance is $30M-$32M; revenue generation is expected to extend the operating runway.

  • COMPASS includes 65 patients in neurologic and somatic/peripheral cohorts; its two-year endpoint is due at end-2027, with readout expected in 2028.

Sanfilippo program

  • A Sanfilippo BLA filing is planned for 2027; the opportunity is considered similar to Hunter syndrome, though prevalence estimates are harder to establish.

  • Initial results in the first eight patients showed an average 80% reduction in CSF heparan sulfate; a subset normalized the biomarker, while higher anti-drug antibodies were seen in some patients.

  • The WORLD 2027 presentation is planned to include all 20 patients, including 12 treated at the intended marketed dose; the dataset will include CSF heparan sulfate and other biomarkers.

  • GM3 normalized in six of seven patients in an earlier dataset; the Phase III confirmatory study has begun and includes Bayley, with Vineland among key secondary endpoints.

  • Enrollment and study design are being considered in light of Ultragenyx’s gene therapy approval, with ongoing FDA engagement on alignment for the program.

FTD-GRN program

  • The progranulin replacement program targets FTD patients with granulin mutations, estimated at 6%-10% of the overall FTD population.

  • Treatment duration was extended from six to 12 months to improve the opportunity to assess proximal lysosomal biomarkers and distal neurofilament light chain, which can take time to change.

  • After reviewing the totality of study data, the team plans to discuss a potential accelerated approval pathway with the FDA; future program steps will depend on the data.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Denali Therapeutics